ETF Portfolio Partners Inc. Buys 118 Shares of Johnson & Johnson (NYSE:JNJ)

ETF Portfolio Partners Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 7.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,779 shares of the company’s stock after buying an additional 118 shares during the quarter. ETF Portfolio Partners Inc.’s holdings in Johnson & Johnson were worth $257,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Stablepoint Partners LLC boosted its stake in shares of Johnson & Johnson by 1.1% in the 4th quarter. Stablepoint Partners LLC now owns 33,465 shares of the company’s stock valued at $4,840,000 after purchasing an additional 371 shares in the last quarter. Clarendon Private LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $276,000. Embree Financial Group grew its stake in Johnson & Johnson by 1.1% during the fourth quarter. Embree Financial Group now owns 20,709 shares of the company’s stock worth $2,995,000 after buying an additional 226 shares during the last quarter. Marshall Financial Group LLC increased its holdings in shares of Johnson & Johnson by 110.9% during the fourth quarter. Marshall Financial Group LLC now owns 11,435 shares of the company’s stock worth $1,654,000 after buying an additional 6,013 shares in the last quarter. Finally, Jamison Private Wealth Management Inc. raised its stake in shares of Johnson & Johnson by 93.7% in the fourth quarter. Jamison Private Wealth Management Inc. now owns 90,537 shares of the company’s stock valued at $13,093,000 after acquiring an additional 43,790 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on JNJ shares. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Johnson & Johnson Stock Performance

JNJ stock opened at $151.27 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $364.20 billion, a PE ratio of 22.75, a P/E/G ratio of 2.45 and a beta of 0.51. The business’s 50-day moving average price is $147.76 and its two-hundred day moving average price is $156.13.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.28%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.